Agios Pharmaceuticals, Inc. announced fourth quarter and full year 2025 financial results, reporting PYRUKYND worldwide net revenues of $20.0 million in Q4 and $54.0 million for the year, AQVESME FDA approval for thalassemia with U.S. availability, and $1.2 billion in cash as of December 31, 2025.
Key takeaways
PYRUKYND U.S. net revenue $16.0 million in Q4 2025 (up 49% from $10.7 million in Q4 2024)
PYRUKYND ex-U.S. net revenue $4.0 million in Q4 2025
Full year 2025 product revenue $54.0 million
Q4 2025 net loss $108.0 million (vs $96.5 million in Q4 2024)
Cash, cash equivalents, and marketable securities $1.2 billion as of December 31, 2025
AQVESME approved by FDA in December 2025 for anemia in adults with alpha- or beta-thalassemia; now available in U.S.